TR199801798T2 - Otizm tedavisi. - Google Patents

Otizm tedavisi.

Info

Publication number
TR199801798T2
TR199801798T2 TR1998/01798T TR9801798T TR199801798T2 TR 199801798 T2 TR199801798 T2 TR 199801798T2 TR 1998/01798 T TR1998/01798 T TR 1998/01798T TR 9801798 T TR9801798 T TR 9801798T TR 199801798 T2 TR199801798 T2 TR 199801798T2
Authority
TR
Turkey
Prior art keywords
treatment
autism treatment
autism
mammals
medicament
Prior art date
Application number
TR1998/01798T
Other languages
English (en)
Inventor
Merritt Beasley Charles
Dennis Tollefson Gary
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199801798T2 publication Critical patent/TR199801798T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Luminescent Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Transplanting Machines (AREA)

Abstract

Bulus olanzapinin etkili bir miktarinin memelilerde otistik bozuklugun ve/veya zihinsel gelisme yetersizliginin tedavisine yönelik bir ilacin imalatinda kullanimina iliskindir.
TR1998/01798T 1996-03-11 1996-12-04 Otizm tedavisi. TR199801798T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1316296P 1996-03-11 1996-03-11

Publications (1)

Publication Number Publication Date
TR199801798T2 true TR199801798T2 (tr) 1998-12-21

Family

ID=21758619

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01798T TR199801798T2 (tr) 1996-03-11 1996-12-04 Otizm tedavisi.

Country Status (19)

Country Link
EP (1) EP0946179B1 (tr)
JP (1) JP2000506860A (tr)
KR (1) KR19990087715A (tr)
CN (1) CN1213970A (tr)
AT (1) ATE249832T1 (tr)
AU (1) AU709181B2 (tr)
BR (1) BR9612552A (tr)
CA (1) CA2248741A1 (tr)
CZ (1) CZ290498A3 (tr)
DE (1) DE69630055T2 (tr)
EA (1) EA000768B1 (tr)
ES (1) ES2206614T3 (tr)
HU (1) HUP9903688A3 (tr)
IL (1) IL126161A0 (tr)
NO (1) NO984197L (tr)
NZ (1) NZ324615A (tr)
PL (1) PL328948A1 (tr)
TR (1) TR199801798T2 (tr)
WO (1) WO1997033585A1 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530341A (ja) * 1998-11-23 2002-09-17 セプラコール, インク. デスメチルオランザピン組成物及び方法
JP2002530339A (ja) 1998-11-23 2002-09-17 セプラコール, インク. 2−ヒドロキシメチルオランザピン組成物及び方法
JP2002530340A (ja) * 1998-11-23 2002-09-17 セプラコール, インク. オランザピン−n−オキサイドを含む医薬組成物
RU2675252C2 (ru) 2012-07-22 2018-12-18 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн МОДУЛЯЦИЯ УРОВНЕЙ sAPP, sAPPα И BDNF У ИНДИВИДУУМОВ С ДИАГНОЗОМ FXS И ASD
EP3058371B1 (en) 2013-10-14 2021-06-16 Indiana University Research and Technology Corporation Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
KR102285577B1 (ko) 2020-11-11 2021-08-04 김의철 자폐를 가진 유소년의 무약물 치료방법 및 시스템

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
CN1213970A (zh) 1999-04-14
ES2206614T3 (es) 2004-05-16
DE69630055D1 (de) 2003-10-23
EA000768B1 (ru) 2000-04-24
PL328948A1 (en) 1999-03-01
WO1997033585A1 (en) 1997-09-18
AU709181B2 (en) 1999-08-26
HUP9903688A2 (hu) 2000-03-28
AU1150197A (en) 1997-10-01
NO984197D0 (no) 1998-09-11
CZ290498A3 (cs) 1999-10-13
IL126161A0 (en) 1999-05-09
HUP9903688A3 (en) 2001-12-28
EP0946179B1 (en) 2003-09-17
JP2000506860A (ja) 2000-06-06
KR19990087715A (ko) 1999-12-27
CA2248741A1 (en) 1997-09-18
EP0946179A4 (en) 2000-04-19
EA199800821A1 (ru) 1999-02-25
DE69630055T2 (de) 2004-06-03
NZ324615A (en) 2000-08-25
ATE249832T1 (de) 2003-10-15
NO984197L (no) 1998-11-03
BR9612552A (pt) 1999-07-20
EP0946179A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
TR200101722T2 (tr) Serivastatin ve fibratların birleşimi.
TR199801798T2 (tr) Otizm tedavisi.
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
DK0841931T3 (da) Farmaceutisk sammensætning
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
MX9203374A (es) Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina.
NO20005548D0 (no) Mykobakterieinhibitorer
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
TR199801800T2 (tr) Uykusuzluk tedavisi.
BR9612549A (pt) Método para tratamento de agressão excessiva
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
BR9708037A (pt) Método para o tratamento de abuso de substância
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
TR199801021T2 (tr) Mide-bagirsak bozukluklarinin önlenmesi ve tedavisi için bizmut içeren bilesimler.
DE59809592D1 (de) Verwendung von putamen ovi
UA28113C2 (uk) Спосіб експрес-тестування ефективності реабілітації здоров'я людини
UA29639A (uk) Протипухлинний засіб